Last reviewed · How we verify
nicotine nasal spray
Nicotine nasal spray delivers nicotine directly to nasal mucosa for rapid systemic absorption to relieve nicotine withdrawal symptoms and support smoking cessation.
Nicotine nasal spray delivers nicotine directly to nasal mucosa for rapid systemic absorption to relieve nicotine withdrawal symptoms and support smoking cessation. Used for Smoking cessation in nicotine-dependent patients.
At a glance
| Generic name | nicotine nasal spray |
|---|---|
| Also known as | nicorette nasal spray, Nicotrol |
| Sponsor | Heinrich-Heine University, Duesseldorf |
| Drug class | Nicotinic receptor agonist |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Smoking Cessation / Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
Nicotine acts as an agonist at nicotinic acetylcholine receptors in the central and peripheral nervous system. The nasal spray formulation provides faster absorption than oral forms, more closely mimicking the rapid nicotine delivery from cigarette smoking. This helps reduce cravings and withdrawal symptoms during smoking cessation attempts.
Approved indications
- Smoking cessation in nicotine-dependent patients
Common side effects
- Nasal irritation
- Rhinitis
- Headache
- Throat irritation
- Cough
- Nausea
Key clinical trials
- Pharmacist Intervention to Improve Smoking Cessation (NA)
- A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV (PHASE4)
- Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use (NA)
- Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care (PHASE4)
- Combination of Acupuncture, Auricular Acupressure and Nicotine Replacement Therapy for Smoking Cessation (NA)
- Neurobehavioral Mechanisms Linking Childhood Adversity to Increased Risk for Smoking (EARLY_PHASE1)
- Nicotine as an Adjuvant Analgesic for Third Molar Surgery (PHASE4)
- Anesthesia and Postoperative Pain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nicotine nasal spray CI brief — competitive landscape report
- nicotine nasal spray updates RSS · CI watch RSS
- Heinrich-Heine University, Duesseldorf portfolio CI